OSI is consolidating its US operations onto a single campus in Ardsley, New York, resulting in it having excess facilities in Melville and Farmingdale, New York, Cedar Knolls, New Jersey and Boulder.
As part of an expanded deal, which came into force on February 1, Novella will occupy some of OSI’s facilities in Boulder and employ staff currently working there. Richard Staub, president and CEO of Novella, believes the expansion will benefit the contract research organisation (CRO).
“As a CRO focused on biotech and medical device companies, many of our clients are located on the west coast and having an office in the western part of the country will allow us to better service their needs”, explained Staub.
In addition to expanding Novella’s geographic reach Staub believes the transferred staff will provide it with further expertise and strengthen its service offering in a key therapeutic area.
OSI’s pipeline is primarily focused on oncology products and consequently its employees have “a depth of experience” in this area. Those that transfer to Novella “will strengthen what is already [its] largest therapeutic category”, according to Staub.
In return Novella will support OSI’s clinical operations, biostatistics, medical writing and regulatory affairs for certain ongoing trials. This is intended to ensure a smooth transition to the campus in Ardsley.
Colin Goddard, CEO of OSI, added: “This is a win-win agreement between OSI and Novella and for the OSI Boulder employees who have chosen not to relocate with the company.”